دورية أكاديمية
أعرض في EDS

Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Naïve CD4+ T Cell Counts Correspond with Delayed Viral Clearance.

التفاصيل البيبلوغرافية
العنوان: Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Naïve CD4+ T Cell Counts Correspond with Delayed Viral Clearance.
المؤلفون: Zlei M; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Sidorov IA; Clinical Microbiological Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Joosten SA; Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Heemskerk MHM; Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Myeni SK; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Pothast CR; Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., de Brouwer CS; Clinical Microbiological Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Boomaars-van der Zanden AL; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., van Meijgaarden KE; Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Morales ST; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Wessels E; Clinical Microbiological Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Janse JJ; Department of Parasitology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Goeman JJ; Medical Statistics Section, Department of Biomedical Data Sciences, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Cobbaert CM; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Kroes ACM; Clinical Microbiological Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Cannegieter SC; Department of Clinical Epidemiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Roestenberg M; Department of Parasitology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Visser LG; Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Kikkert M; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Feltkamp MCW; Clinical Microbiological Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Arbous SM; Department of Clinical Epidemiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.; Department of Intensive Care, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Staal FJT; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Ottenhoff THM; Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., van Dongen JJM; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Roukens AHE; Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., de Vries JJC; Clinical Microbiological Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., In Collaboration With Beat-Covid, In Collaboration With Lumc Covid
المصدر: Cells [Cells] 2022 Sep 02; Vol. 11 (17). Date of Electronic Publication: 2022 Sep 02.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: COVID-19*, Antibodies, Viral ; CD4-Positive T-Lymphocytes ; Critical Illness ; Humans ; SARS-CoV-2
مستخلص: Virus-specific cellular and humoral responses are major determinants for protection from critical illness after SARS-CoV-2 infection. However, the magnitude of the contribution of each of the components to viral clearance remains unclear. Here, we studied the timing of viral clearance in relation to 122 immune parameters in 102 hospitalised patients with moderate and severe COVID-19 in a longitudinal design. Delayed viral clearance was associated with more severe disease and was associated with higher levels of SARS-CoV-2-specific (neutralising) antibodies over time, increased numbers of neutrophils, monocytes, basophils, and a range of pro-inflammatory cyto-/chemokines illustrating ongoing, partially Th2 dominating, immune activation. In contrast, early viral clearance and less critical illness correlated with the peak of neutralising antibodies, higher levels of CD4 T cells, and in particular naïve CD4+ T cells, suggesting their role in early control of SARS-CoV-2 possibly by proving appropriate B cell help. Higher counts of naïve CD4+ T cells also correlated with lower levels of MIF, IL-9, and TNF-beta, suggesting an indirect role in averting prolonged virus-induced tissue damage. Collectively, our data show that naïve CD4+ T cell play a critical role in rapid viral T cell control, obviating aberrant antibody and cytokine profiles and disease deterioration. These data may help in guiding risk stratification for severe COVID-19.
References: J Immunol. 2014 Mar 15;192(6):2689-98. (PMID: 24510963)
J Clin Virol. 2020 Dec;133:104663. (PMID: 33161369)
Cell Rep Med. 2020 Sep 22;1(6):100092. (PMID: 32904468)
Cell Rep. 2021 Feb 9;34(6):108728. (PMID: 33516277)
Methods Mol Biol. 2020;2099:107-116. (PMID: 31883091)
Nat Commun. 2020 Oct 30;11(1):5493. (PMID: 33127906)
Nat Commun. 2021 Sep 23;12(1):5621. (PMID: 34556667)
Sci Rep. 2021 Jan 21;11(1):2062. (PMID: 33479465)
Int Immunopharmacol. 2020 Dec;89(Pt A):107031. (PMID: 33039964)
J Virol. 2010 Feb;84(3):1289-301. (PMID: 19906920)
Ann Stat. 2016 Jun;44(3):1103-1130. (PMID: 27340305)
Nat Med. 2020 Oct;26(10):1636-1643. (PMID: 32839624)
Cell Mol Immunol. 2021 Mar;18(3):604-612. (PMID: 33060840)
Cell Death Dis. 2020 Nov 6;11(11):957. (PMID: 33159040)
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. (PMID: 32221519)
Nature. 2020 Aug;584(7821):457-462. (PMID: 32668444)
J Immunol Methods. 2019 Dec;475:112287. (PMID: 28341440)
Cell Rep Med. 2022 Feb 25;3(3):100562. (PMID: 35474748)
PLoS One. 2018 Sep 4;13(9):e0201205. (PMID: 30180167)
Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387)
J Clin Microbiol. 2018 Mar 26;56(4):. (PMID: 29305551)
Front Immunol. 2021 Nov 10;12:748881. (PMID: 34858405)
Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127)
Nat Immunol. 2022 Jan;23(1):23-32. (PMID: 34937933)
Cell Mol Immunol. 2021 Feb;18(2):318-327. (PMID: 33408342)
J Clin Virol. 2020 Aug;129:104468. (PMID: 32485620)
Cell. 2020 Nov 12;183(4):996-1012.e19. (PMID: 33010815)
Nat Immunol. 2022 Feb;23(2):186-193. (PMID: 35105982)
Front Immunol. 2019 Mar 04;10:246. (PMID: 30886612)
Nat Commun. 2021 May 11;12(1):2670. (PMID: 33976165)
Immunity. 2021 May 11;54(5):1066-1082.e5. (PMID: 33951417)
Nat Microbiol. 2020 Dec;5(12):1598-1607. (PMID: 33106674)
Sci Immunol. 2020 Jun 26;5(48):. (PMID: 32591408)
Proc Natl Acad Sci U S A. 2022 Jan 4;119(1):. (PMID: 34937699)
Front Immunol. 2021 Jul 13;12:693054. (PMID: 34326844)
Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
Front Immunol. 2020 Sep 17;11:570018. (PMID: 33042151)
Front Immunol. 2019 Jun 13;10:1271. (PMID: 31263462)
Emerg Infect Dis. 2011 Aug;17(8):1355-63. (PMID: 21801610)
Lancet Microbe. 2020 Nov;1(7):e290-e299. (PMID: 33015653)
Signal Transduct Target Ther. 2020 Jul 25;5(1):128. (PMID: 32712629)
Sci Rep. 2020 Nov 16;10(1):19893. (PMID: 33199713)
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):. (PMID: 33536313)
Nat Med. 2020 May;26(5):672-675. (PMID: 32296168)
Immunity. 2020 Oct 13;53(4):864-877.e5. (PMID: 32791036)
Nat Immunol. 2022 Feb;23(2):165-176. (PMID: 35105981)
Nat Commun. 2020 Sep 17;11(1):4704. (PMID: 32943637)
Cancer Cell. 2020 Nov 9;38(5):661-671.e2. (PMID: 32997958)
Vaccine. 2021 Jul 22;39(32):4423-4428. (PMID: 34210573)
BMJ. 2020 Apr 21;369:m1443. (PMID: 32317267)
Lancet. 2020 Nov 14;396(10262):1595-1606. (PMID: 33065034)
Nat Rev Immunol. 2020 Jun;20(6):363-374. (PMID: 32346093)
Front Immunol. 2021 Feb 17;11:603972. (PMID: 33679693)
فهرسة مساهمة: Keywords: COVID-19; naïve CD4+ T cell; viral clearance
المشرفين على المادة: 0 (Antibodies, Viral)
تواريخ الأحداث: Date Created: 20220909 Date Completed: 20220913 Latest Revision: 20221126
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9455062
DOI: 10.3390/cells11172743
PMID: 36078151
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4409
DOI:10.3390/cells11172743